- Home
- AMLX
as of 03-10-2026 3:56pm EST
$14.98
+$0.67
+4.68%
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 1.3B | IPO Year: | 2021 |
| Target Price: | $19.56 | AVG Volume (30 days): | 808.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.53 | EPS Growth: | 65.46 |
| 52 Week Low/High: | $3.11 - $17.49 | Next Earning Date: | 06-08-2026 |
| Revenue: | $380,786,000 | Revenue Growth: | 1612.94% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -9.04 | Index: | N/A |
| Free Cash Flow: | -123481000.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of Amylyx Pharmaceuticals Inc. (AMLX)
Cohen Joshua B
Sell
Co-Chief Executive Officer
AMLX Mar 2, 2026
Avg Cost/Share
$14.48
Shares
29,282
Total Value
$424,120.49
Owned After
3,334,683
SEC Form 4
Mazzariello Gina
Sell
Chief Legal Officer
AMLX Mar 2, 2026
Avg Cost/Share
$14.52
Shares
6,844
Total Value
$99,378.30
Owned After
134,430
SEC Form 4
Klee Justin B.
Sell
Co-Chief Executive Officer
AMLX Mar 2, 2026
Avg Cost/Share
$14.47
Shares
29,282
Total Value
$423,760.32
Owned After
3,334,616
SEC Form 4
Bedrosian Camille L
Sell
Chief Medical Officer
AMLX Mar 2, 2026
Avg Cost/Share
$14.58
Shares
6,461
Total Value
$94,205.26
Owned After
169,295
SEC Form 4
FRATES JAMES M
Sell
Chief Financial Officer
AMLX Mar 2, 2026
Avg Cost/Share
$14.52
Shares
7,909
Total Value
$114,851.33
Owned After
165,638
SEC Form 4
Mazzariello Gina
Sell
Chief Legal Officer
AMLX Feb 23, 2026
Avg Cost/Share
$14.14
Shares
3,419
Total Value
$48,352.18
Owned After
134,430
SEC Form 4
Cohen Joshua B
Sell
Co-Chief Executive Officer
AMLX Feb 2, 2026
Avg Cost/Share
$14.68
Shares
15,500
Total Value
$227,592.70
Owned After
3,334,683
SEC Form 4
Mazzariello Gina
Sell
Chief Legal Officer
AMLX Feb 2, 2026
Avg Cost/Share
$14.65
Shares
3,448
Total Value
$50,515.61
Owned After
134,430
SEC Form 4
Klee Justin B.
Sell
Co-Chief Executive Officer
AMLX Feb 2, 2026
Avg Cost/Share
$14.69
Shares
15,500
Total Value
$227,617.50
Owned After
3,334,616
SEC Form 4
FRATES JAMES M
Sell
Chief Financial Officer
AMLX Feb 2, 2026
Avg Cost/Share
$14.65
Shares
3,557
Total Value
$52,096.89
Owned After
165,638
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Cohen Joshua B | AMLX | Co-Chief Executive Officer | Mar 2, 2026 | Sell | $14.48 | 29,282 | $424,120.49 | 3,334,683 | |
| Mazzariello Gina | AMLX | Chief Legal Officer | Mar 2, 2026 | Sell | $14.52 | 6,844 | $99,378.30 | 134,430 | |
| Klee Justin B. | AMLX | Co-Chief Executive Officer | Mar 2, 2026 | Sell | $14.47 | 29,282 | $423,760.32 | 3,334,616 | |
| Bedrosian Camille L | AMLX | Chief Medical Officer | Mar 2, 2026 | Sell | $14.58 | 6,461 | $94,205.26 | 169,295 | |
| FRATES JAMES M | AMLX | Chief Financial Officer | Mar 2, 2026 | Sell | $14.52 | 7,909 | $114,851.33 | 165,638 | |
| Mazzariello Gina | AMLX | Chief Legal Officer | Feb 23, 2026 | Sell | $14.14 | 3,419 | $48,352.18 | 134,430 | |
| Cohen Joshua B | AMLX | Co-Chief Executive Officer | Feb 2, 2026 | Sell | $14.68 | 15,500 | $227,592.70 | 3,334,683 | |
| Mazzariello Gina | AMLX | Chief Legal Officer | Feb 2, 2026 | Sell | $14.65 | 3,448 | $50,515.61 | 134,430 | |
| Klee Justin B. | AMLX | Co-Chief Executive Officer | Feb 2, 2026 | Sell | $14.69 | 15,500 | $227,617.50 | 3,334,616 | |
| FRATES JAMES M | AMLX | Chief Financial Officer | Feb 2, 2026 | Sell | $14.65 | 3,557 | $52,096.89 | 165,638 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Mar 3, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYMar 3, 2026 · 100% conf.
AI Prediction BUY
1D
+1.71%
$14.35
Act: +6.66%
5D
+11.27%
$15.70
20D
+4.93%
$14.81
Price: $14.11 Prob +5D: 100% AUC: 1.000
0001193125-26-086629
8-K
0001658551false00016585512026-03-032026-03-03
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2026
AMYLYX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-41199
46-4600503
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
55 Cambridge Parkway, Suite 6W Cambridge, Massachusetts
02142
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (617) 682-0917 Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.0001 par value per share
AMLX
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On March 3, 2026, Amylyx Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Form 8-K”). The information provided in this Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits (d) Exhibits.
Exhibit Number
Description
99.1
Press Release of the Company, dated March 3, 2026
104
Cover Page Interactive Data File (embedded with the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AMYLYX PHARMACEUTICALS, INC.
Date: March 3, 2026
By:
/s/ James M. Frates
James M. Frates
Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K Nov 6, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 6, 2025
0001193125-25-268043
8-K
false000165855100016585512025-11-062025-11-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025
AMYLYX PHARMACEUTICALS, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-41199
46-4600503
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
43 Thorndike St., Cambridge, MA
02141
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (617) 682-0917 Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.0001 par value per share
AMLX
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On November 6, 2025, Amylyx Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 hereto. The information provided in this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits.
Exhibit Number
Description
99.1
Press Release of the Company, dated November 6, 2025
104
Cover Page Interactive Data File (embedded with the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AMYLYX PHARMACEUTICALS, INC.
Date: November 6, 2025
By:
/s/ James M. Frates
James M. Frates
Chief Financial Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 7, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 7, 2025
0000950170-25-104546
8-K
false000165855100016585512025-08-072025-08-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025
AMYLYX PHARMACEUTICALS, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-41199
46-4600503
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
43 Thorndike St., Cambridge, MA
02141
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (617) 682-0917 Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.0001 par value per share
AMLX
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On August 7, 2025, Amylyx Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 hereto. The information provided in this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits.
Exhibit Number
Description
99.1
Press Release of the Company, dated August 7, 2025
104
Cover Page Interactive Data File (embedded with the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AMYLYX PHARMACEUTICALS, INC.
Date: August 7, 2025
By:
/s/ James M. Frates
James M. Frates
Chief Financial Officer
Latest Amylyx Pharmaceuticals Inc. News
AMLX Breaking Stock News: Dive into AMLX Ticker-Specific Updates for Smart Investing
Compare AMLX vs Leading Stocks
See how AMLX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "AMLX Amylyx Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.